Adequate amounts of magnesium in the diet could reduce the risk of type 2 and cerebral vascular incidents.Read More »
Long-term users of the acid reflux drugs known as Proton Pump Inhibitors (PPIs) have a 24% higher risk of developing type 2 diabetes than non-PPI users.Read More »
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?Read More »
Dual and triple therapy just got a little easier.Read More »
Insulin delivery method or blood glucose monitoring – which is more important?Read More »
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.Read More »
Can a virtual diabetes clinic (VDC) improve diabetes care?Read More »
The study aimed to investigate whether testing HbA1c will improve cardiovascular disease risk assessment.Read More »
Optimize Clinical Diabetes Management with AI Technology
A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs.
In part 3: user testimonials about the experience and exciting findings using the software. A more in-depth examination of the benefits of applying decision-support software in clinical practice.
Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors?Read More »